MAPS Public Benefit Corporation (PBC) has submitted its New Drug Application (NDA) to the FDA in order to seek marketing approval of MDMA-assisted therapy (MDMA-AT) for PTSD.The organisation and its parent non-profit, MAPS, has been conducting clinical studies of MDMA-AT for over twenty years, making this a significant milestone.And it’s not just a milestone for MAPS: this is the first psychedelic…
